Cagrilintide,China Factory Supply Lyophilized Powder Cagrilintide Weight Loss,99% high-purity,available in stock in the warehouse,on-time shipment
TDS 35 Inquiries
129954-34-3
Cosmetics Grade
99.9%
XiangGang
DS
5mg*10vials 10mg*10vials 40mg*10vials
2026-09-12
Medical and health products,Peptide products
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceSELANK Synthetic is a single, non-glycosylated polypeptide chain containing 7 amino acids, having a molecular mass of 751.89 Dalton and a Molecular formula of C33H57N11O9.CertificatesBasic Info
-
Product Name:
Selank peptide
Other Name:Selank peptide;SelankAcetate;PL14736;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline;L-THREONYL-L-LYSYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYL-L-PROLINE; MONOACETATE;H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH;SLANK;Selank peptid
CAS No.:129954-34-3
Molecular Formula:C33H57N11O9
InChIKeys:JTDTXGMXNXBGBZ-YVHUGQOKSA-N
Molecular Weight:751.87
Exact Mass:751.43407244
EC Number:232-660-2
UNII:TS9JR8EP1G
Categories:
Characteristics-
Density:
1.53±0.1 g/cm3(Predicted)
Melting Point:134-136 °C
PKA:3.43±0.20(Predicted)
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medical and health products,Peptide products
-
Location:
Room 210, 2nd Floor, Office Building No.1, Dezhou Fushite Electric Motor Co., Ltd., North of Xiaoli Road and West of Tianlong Village, Tianqu Sub-district Office
-
Payment Terms:
100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA
-
-
Inquiry History35 Inquiries
Country Product Purchase Quantity Date Posted
United States
Selank 99% Purity 129954-34-3
1 G Jan 23, 2026
Greece
selank
10 MG May 20, 2026
United States
N acetyl selank
500 MG Apr 30, 2026
United States
Selank
100 MG Apr 24, 2026
Italy
Nacetyl selank
1 MT Apr 22, 2026
Oman
Selank
1 G Mar 4, 2026
United States
Selank
30 40' Fcl Oct 14, 2025
United States
selank
30 MG May 25, 2026
Brazil
Selank
10 MT Apr 7, 2026
United States
selank
1 G Mar 13, 2026
United States
Selank
1 G Mar 9, 2026
United Kingdom
Selank
1 G Dec 22, 2025
United States
Selank
20 MG Nov 10, 2025
United States
NA-Selank Amidate
10 MG Sep 18, 2025
United Kingdom
Selank
100 MG Jul 15, 2025
United States
N-Acetyl Selank Amidate
1 KG Jan 9, 2025
United States
Selank
10 Mar 29, 2024
Poland
Selank
10 G Feb 18, 2024
United States
Selank
1 G Jan 27, 2024
United States
selank
100 MG Jul 7, 2026 Post an enquiry for this product
